Artiva Biotherapeutics, Inc. (ARTV)
4.20
+0.01
(+0.24%)
USD |
NASDAQ |
Nov 03, 16:00
4.20
0.00 (0.00%)
After-Hours: 19:38
Artiva Biotherapeutics Enterprise Value : -135.11M for Nov. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 02, 2026 | -135.11M |
| October 30, 2026 | -135.11M |
| October 29, 2026 | -133.15M |
| October 28, 2026 | -130.96M |
| October 27, 2026 | -131.20M |
| October 26, 2026 | -38.98M |
| October 23, 2026 | -39.47M |
| October 22, 2026 | -37.03M |
| October 21, 2026 | -22.88M |
| October 20, 2026 | -19.47M |
| October 19, 2026 | -52.16M |
| October 16, 2026 | -54.11M |
| October 15, 2026 | -43.86M |
| October 14, 2026 | -51.18M |
| October 13, 2026 | -32.64M |
| October 12, 2026 | -9.221M |
| October 09, 2026 | -0.9264M |
| October 08, 2026 | -7.757M |
| October 07, 2026 | 2.001M |
| October 06, 2026 | 15.18M |
| October 05, 2026 | 8.344M |
| October 02, 2026 | -6.294M |
| October 01, 2026 | -8.245M |
| September 30, 2026 | 7.856M |
| September 29, 2026 | 3.465M |
| Date | Value |
|---|---|
| September 28, 2026 | 4.441M |
| September 25, 2026 | 1.513M |
| September 24, 2026 | 25.91M |
| September 23, 2026 | 37.13M |
| September 22, 2026 | 55.18M |
| September 21, 2026 | 42.50M |
| September 18, 2026 | 80.56M |
| September 17, 2026 | 72.26M |
| September 16, 2026 | 80.07M |
| September 15, 2026 | 95.19M |
| September 14, 2026 | 155.21M |
| September 11, 2026 | 159.11M |
| September 10, 2026 | 168.87M |
| September 09, 2026 | 186.92M |
| September 08, 2026 | 191.32M |
| September 04, 2026 | 206.44M |
| September 03, 2026 | 203.27M |
| September 02, 2026 | 212.30M |
| September 01, 2026 | 210.83M |
| August 31, 2026 | 211.81M |
| August 28, 2026 | 201.56M |
| August 27, 2026 | 243.04M |
| August 26, 2026 | 234.74M |
| August 25, 2026 | 234.74M |
| August 24, 2026 | 222.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.182B |
| Oncolytics Biotech, Inc. | 46.19M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.192B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.00M |
| Total Expenses (Quarterly) | 25.00M |
| EPS Diluted (Quarterly) | -0.6344 |
| Earnings Yield | -78.86% |
| Normalized Earnings Yield | -78.86 |